From Research at med.fsu.edu Wed Apr 1 12:59:03 2020 From: Research at med.fsu.edu (Med Research) Date: Wed, 1 Apr 2020 16:59:03 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE01FC5EB185@FSUCOM128.med.ad.fsu.edu> Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R21 / R01 Clinical Trial Optional) R21 R01 These FOAs seek innovative research to optimize HIV prevention and care that is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches, and intervention efficacy or effectiveness trials. Applicants are encouraged to read current Notices of Special Interests from NIMH DAR for further information about the Division?s research priorities. Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for May 7, 2020 standard date: April 27. Michael J. Fox Foundation: Investigating Environmental Factors that Increase the Risk for Parkinson?s Disease While some evidence links environmental factors with increased risk of PD, according to the foundation much remains unknown regarding the specific environmental risks, their role in disease, and the quantification of their contributions. A better understanding of environmental risk factors for PD could lead to efforts to reduce or prevent such exposures. To that end, grants of up to $400,000 over up to two years will be awarded in support of investigations into environmental factors. Applications should focus on studies that achieve the following goals: * Analyze large epidemiological datasets to identify environmental risk factors, such as exposure to chemicals, toxic emissions, air pollutants, and dietary contaminants, which are associated with an increased risk of PD. * MJFF is especially interested in funding projects that utilize large longitudinal datasets and will prioritize collaborative efforts that bring together teams of investigators with access to multiple diverse datasets. This program is not appropriate for studies that require additional or prospective data collection. Pre-proposal due May 14, 2020. Med-RA deadline to receive draft documents: May 4. Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required) This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH designated areas of high research priority. Applications submitted under this FOA are expected to propose a remotely delivered and conducted clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. To justify the proposed remotely delivered efficacy or effectiveness clinical trial, applications must have sufficient preliminary data that includes: demonstration of feasibility of remote recruitment and accrual of participants; demonstration of participant adherence to the intervention as well as retention of participants throughout the study; completion of final data collection from any related studies; demonstration of the safety of the intervention; and evidence that the intervention has promise of clinical benefit. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26. Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease. A distinguishing feature of each application to this FOA will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the FOA acts more as funding mechanism for driving translational research in imaging more than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation. Standard dates apply. Expires September 8, 2022. Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26. Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer?s Disease (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) enables data-driven drug repositioning and combination therapy for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) by developing computational methods and data resources and/or integrating computational approaches with proof-of-concept efficacy studies in cell-based models, animal models, and/or humans. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26. Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required) This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trialsto improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26. Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer?s Dementia (R21 / R01 Clinical Trial Optional) R21 R01 The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer?s disease (AD) or Alzheimer?s disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26. Med-RA deadline to receive draft documents for June 16, 2020 R21 standard date: June 3. NIMHD Exploratory/Developmental Research Grant Program (R21 ? Clinical Trial Optional) NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S. Standard dates apply. Expires June 17, 2023. Med-RA deadline to receive draft documents for June 16, 2020 standard date: June 3. NIDA Small Research Grant Program (R03 Clinical Trial Required) The NIDA Small Research Grant Program supports small clinical trials that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot, feasibility, or small clinical trials with medications, behavioral interventions, immunotherapies, therapeutic devices, therapeutic digital applications, health services, prevention interventions, biomarkers, and development of research methodology. This Funding Opportunity Announcement requires that a clinical trial be proposed. The proposed project must be related to the programmatic interests of NIDA. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 16, 2020 standard date: June 3. NIH Science Education Partnership Award (SEPA) (R25) The NIH Research Education Program (R25) supports research educational activities that complement other formal training programs in the mission areas of the NIH Institutes and Centers. The over-arching goals of the NIH R25 program are to: (1) complement and/or enhance the training of a workforce to meet the nation?s biomedical, behavioral and clinical research needs; (2) encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research; (3) help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences; and (4) foster a better understanding of biomedical, behavioral and clinical research and its implications. The SEPA program supports P-12 and informal science education (ISE) activities that: (1) enhance the diversity of the biomedical, behavioral and clinical research workforce and (2) foster a better understanding of NIH-funded biomedical, behavioral and clinical research and its public health implications. The SEPA program targets two primary audiences: (1) SEPA formal or classroom-based projects, provide STEM content, pedagogical expertise, and problem solving skills to teachers, students, and families in communities not generally supported by advanced and innovative educational practices: (2) SEPA ISE activities, conducted in outside-the-classroom venues as well as in science centers and museums, target both workforce diversity and improved public health literacy. Applications that target pre-kindergarten to grade 12 (P-12) or ISE topics that are not being addressed by existing school, community, or ISE-based activities are encouraged. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation?s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: * Courses for Skills Development * Research Experiences * Mentoring Activities * Curriculum or Methods Development * Outreach Due July 14, 2020; July 13, 2021; and July 13, 2022. Med-RA deadline to receive draft documents for July 14, 2020 deadline: July 1. Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to support high risk, high impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high risk, high impact nature of this research, this FOA supports a Go/No-Go approach to funding high risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent upon achieving negotiated ?Go/No-Go? criteria by the end of Year 2. Due July 28, 2020; July 28, 2021; and July 28, 2022. Med-RA deadline to receive draft documents for July 28, 2020 deadline: July 15. Long Acting Treatments for HIV and HIV-Associated Co-Infections (R61 / R33 Clinical Trial Not Allowed) The purpose of this Funding Opportunity is to stimulate new and innovative multidisciplinary research in the area of long acting therapeutics for HIV and HIV-associated tuberculosis and viral hepatitis B and C. Applications are sought that lead to new effective therapies for administration once per month or less frequently as oral, injectable, implantable, or transdermal products. Due July 28, 2020. Med-RA deadline to receive draft documents: July 15. Congressionally Directed Medical Research Programs Lung Cancer Research Program Career Development Award Pre-application (required letter of intent): July 15, 2020. Application: July 29, 2020. Clinical Translational Research Partnership Award Pre-application (required letter of intent): July 15, 2020. Application: July 29, 2020. Med-RA deadline to receive pre-application draft documents: July 6. Neurofibromatosis Research Program Clinical Trial Award Pre-application (letter of intent): June 25, 2020. Application: July 9, 2020. Exploration ? Hypothesis Development Award Pre-application (letter of intent): June 25, 2020. Application: July 9, 2020. New Investigator Award Pre-application (letter of intent): June 25, 2020. Application: July 9, 2020. Early Investigator Research Award Pre-application (letter of intent): June 25, 2020. Application: July 9, 2020. Confidential letters of recommendation: July 14, 2020. Med-RA deadline to receive pre-application draft documents: June 15. Peer Reviewed Cancer Research Program Virtual Cancer Center Director Award Pre-application (letter of intent): July 30, 2020. Application: August 20, 2020. Career Development Award ? Fellow Option Pre-application (letter of intent): July 30, 2020. Application: August 20, 2020. Career Development Award ? Virtual Cancer Center Scholar Option Pre-application (letter of intent): July 30, 2020. Application: August 20, 2020. Med-RA deadline to receive pre-application draft documents: July 20. Idea Award Pre-application (preproposal): May 14, 2020. Invited full application: August 27, 2020. Impact Award Pre-application (preproposal): May 14, 2020. Invited full application: August 27, 2020. Med-RA deadline to receive pre-application draft documents: May 4. Behavioral Health Science Award Pre-application (letter of intent): July 30, 2020. Application: August 20, 2020. Translational Team Science Award Pre-application (letter of intent): July 30, 2020. Application: August 20, 2020. Med-RA deadline to receive pre-application draft documents: July 20. Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21 / R01 ? Clinical Trial Not Allowed) R21 R01 The purpose of these FOAs is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders and/or HIV infection, latency, or pathogenesis in the CNS. Applicants may propose to investigate biological mechanisms involving exRNA carrier subclasses, or propose to develop improved technologies to investigate extracellular vesicles or other exRNA carriers. Non-AIDs Due October 13, 2020; March 15, 2021; October 13, 2021; March 15, 2022; October 13, 2022; and March 15, 2023. Med-RA deadline to receive draft documents for October 13, 2020 deadline: September 30. AIDS Due January 7, 2021; May 7, 2021; January 7, 2022; May 7, 2022; January 7, 2023; and May 7, 2023. Med-RA deadline to receive draft documents for January 7, 2021 deadline: December 18, 2020. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Fri Apr 3 12:43:24 2020 From: Research at med.fsu.edu (Med Research) Date: Fri, 3 Apr 2020 16:43:24 +0000 Subject: FW: Collaborative Collision: COVID-19 In-Reply-To: References: Message-ID: <60E19361B71BE04F835C1FB3C18361BE01FC5ED23E@FSUCOM128.med.ad.fsu.edu> Delivered on behalf of Dr. Jeffrey Joyce Jeffrey N. Joyce, Ph.D. Senior Associate Dean for Research and Graduate Programs Professor of Biomedical Sciences Florida State University College of Medicine Suite 1110-J 1115 Call Street Tallahassee, FL 32306-4300 850-644-2190 Email Jeffrey.Joyce at med.fsu.edu Learn More: https://med.fsu.edu/researchdivision/home -------------------------------------------------------------------------------- Selene Borras Senior Administrative Specialist for the Division of Research and Graduate Programs Email: selene.borras at med.fsu.edu Office: 850-644-2237 Fax (850) 645-1420 1115 West Call Street Room 1110-H Tallahassee, Florida 32306-4300 [cid:image001.jpg at 01D2A190.6117FBD0] Please note: Florida has very broad public record laws. Most written communications to or from state/university employees and students are public records and available to the public and media upon request. Your email communications may therefore be subject to public disclosure From: Mike Mitchell [mailto:mike.mitchell at fsu.edu] Sent: Thursday, April 2, 2020 10:53 AM To: Robert Reiser >; Farrukh Alvi >; Courtney Cahill >; Rob Contreras >; Jennifer Copp >; Tarik Dogru >; Joseph Grzywacz >; Mark Horner >; Joyce, Jeffrey >; Marcia Mardis >; Kathleen McCullough >; Graham McDougall >; Meredith McQuerry >; Michael Meth >; Scott Shamp >; Jayne Standley >; Andrew Syder >; Stephen Tripodi >; Latika Young > Cc: Beth Hodges > Subject: Collaborative Collision: COVID-19 Importance: High [Notice: This email originated outside of the College of Medicine.] ________________________________ Good Morning CADR Members, Would you please share this with your faculty: The Office of Research Development invites Florida State University?s research community, as well as State and Local organizations, to participate in an online networking event focused on research and community response related to the ongoing COVID-19 pandemic. This unique online Collaborative Collision event will connect FSU researchers working in areas relevant to COVID-19 response to each other, and will also allow potential State and Local partners to understand the unique skills and expertise of FSU?s research community. As we have seen in the past few days and weeks, skills and assets can be rapidly repurposed to help address this crisis, and we encourage all FSU faculty, considering COVID-19 research efforts directly or tangentially, to engage in this online event. Collaborative Collisions are FSU?s premier interdisciplinary research networking events, and are routinely attended by 75-100 faculty members from all of our colleges, departments, and research centers. Collaborative Collision: COVID-19 will be a Zoom-based event that will follow our presentation-style Collaborative Collision format. Each presenter will submit a single presentation slide to ORD, and will have three minutes to pitch their needs and/or interests to the group. Immediately following the event, all participants will receive a copy of the presented slides, access to the recorded event, and ORD will further facilitate follow-up discussions. Our Virtual Collaborative Collision: COVID-19 will take place next Friday, April 10th, from 3-6pm. Registration for this event is now open at: https://www.research.fsu.edu/research-offices/ord/collaborative-collision/registration-page/ (Zoom invitations will be sent only to those who register by April 9th). If you have any questions, please feel free to email me at mike.mitchell at fsu.edu Thanks, Mike Mitchell Program Manager Strategic Initiatives and Proposal Development Office of Research Development Florida State University 2019 Westcott North Annex P 850.644.9511 mike.mitchell at fsu.edu http://www.research.fsu.edu/opd/ -------------- next part -------------- An HTML attachment was scrubbed... URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: image001.jpg Type: image/jpeg Size: 12774 bytes Desc: image001.jpg URL: From Research at med.fsu.edu Mon Apr 6 09:22:05 2020 From: Research at med.fsu.edu (Med Research) Date: Mon, 6 Apr 2020 13:22:05 +0000 Subject: New COVID-19 funding opportunities and resources site In-Reply-To: References: Message-ID: <60E19361B71BE04F835C1FB3C18361BE01FC5ED2DA@FSUCOM128.med.ad.fsu.edu> Forwarded on behalf of Dr. Jeffrey Joyce. Reminder: please notify Med-RA of your intent to respond to any funding announcement: research at med.fsu.edu. Jeffrey N. Joyce, Ph.D. Senior Associate Dean for Research and Graduate Programs Professor of Biomedical Sciences Florida State University College of Medicine Suite 1110-J 1115 Call Street Tallahassee, FL 32306-4300 850-644-2190 Email Jeffrey.Joyce at med.fsu.edu Learn More: https://med.fsu.edu/researchdivision/home -------------------------------------------------------------------------------- Selene Borras Senior Administrative Specialist for the Division of Research and Graduate Programs Email: selene.borras at med.fsu.edu Office: 850-644-2237 Fax (850) 645-1420 1115 West Call Street Room 1110-H Tallahassee, Florida 32306-4300 [cid:image001.jpg at 01D2A190.6117FBD0] Please note: Florida has very broad public record laws. Most written communications to or from state/university employees and students are public records and available to the public and media upon request. Your email communications may therefore be subject to public disclosure From: Beth Hodges [mailto:bhodges at fsu.edu] Sent: Monday, April 6, 2020 8:50 AM To: Andrew Syder >; Joyce, Jeffrey >; Jennifer Copp >; Courtney Cahill >; Mark Dobek >; Tarik Dogru >; Farrukh Alvi >; Graham McDougall >; Jayne Standley >; Joseph Grzywacz >; Kathleen McCullough >; Latika Young >; Marcia Mardis >; Mark Horner >; Meredith McQuerry >; Michael Meth >; Rob Contreras >; Robert Reiser >; Scott Shamp >; Stephen Tripodi > Subject: New COVID-19 funding opportunities and resources site [Notice: This email originated outside of the College of Medicine.] ________________________________ Associate Deans for Research, Good morning. I wanted to make you all aware, in case you didn?t see it in the announcements site last week, that we have created a COVID-19 funding opportunities and resources site. This will be continually updated as information becomes available. Please note that turn-around times on many of the funding opportunities are very short so folks need to move quickly if there is interest. I am adding a ?date posted? column today so that faculty can view the most recent posted if they like. The site is also keyword searchable. Questions? Just let me know. https://www.research.fsu.edu/research-offices/ord/funding-opportunities-related-to-covid-19/ Also, as a reminder, there will be a virtual COVID-19 Collaborative Collision THIS FRIDAY. If you have colleagues interested, they should sign up TODAY, if they have not already. https://www.research.fsu.edu/research-offices/ord/collaborative-collision/registration-page/ Beth Beth E. Hodges Director Office of Research Development Florida State University bhodges at fsu.edu 850.644.2257 -------------- next part -------------- An HTML attachment was scrubbed... URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: image001.jpg Type: image/jpeg Size: 12774 bytes Desc: image001.jpg URL: From Research at med.fsu.edu Thu Apr 9 13:54:23 2020 From: Research at med.fsu.edu (Med Research) Date: Thu, 9 Apr 2020 17:54:23 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE01FC5ED5A2@FSUCOM128.med.ad.fsu.edu> Gordon and Betty Moore Foundation: Development of Clinical Quality Measures to Improve Diagnosis In November 2018, the Moore Foundation announced its Diagnostic Excellence Initiative, which aims to reduce harm from erroneous or delayed diagnoses, reduce costs and redundancy in the diagnostic process, improve health outcomes, and save lives. According to the foundation, twelve million Americans experience a diagnostic error each year, with diagnostic errors playing a role in an estimated 40,000 to 80,000 deaths annually in the U.S. In short, there is an urgent need to improve diagnosis; however, without an awareness of baseline performance and standards against which to compare performance, there is no way to measure improvement or to gauge the results of interventions. Despite a lengthy and growing list of clinical quality measures in health care, few existing measures address diagnostic performance specifically. The challenge of finding meaningful clinical measures for diagnosis reflects the complexity of the diagnostic process. To that end, grants of up to $500,000 over eighteen months will be awarded to support the development of innovative clinical quality measures that promote excellence in diagnosis of three categories of disease, acute vascular events (such as stroke and myocardial infarction), infections (such as sepsis and pneumonia), and cancer (such as lung and colorectal cancer). The expected work requires two interlinked activities: 1) development of the rationale for a measure, and 2) operationalizing the measure into an algorithm that can undergo pilot (or proof-of-concept) testing. Proposals should include teams and partnerships that include a multidisciplinary group of experts, including clinicians with content expertise, individuals with appropriate analytic expertise (data science, statistics, measure development), and persons with experience using relevant data sources. Due May 4, 2020. Med-RA deadline to receive draft documents: April 21. American Association for Cancer Research: Transformative Cancer Research The AACR NextGen Grants for Transformative Cancer Research represent a funding initiative to stimulate highly innovative research from young investigators. This grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that may not be funded through conventional channels. It is expected that these grants will catalyze significant scientific discoveries and help talented young investigators gain scientific independence. The proposed research must represent a highly innovative approach to a major challenge in cancer and have the potential to lead to groundbreaking discoveries in the field and transform our understanding of the tumorigenesis process and/or our ability to treat, detect, or prevent cancer. The research can be in any area of basic, translational, or clinical science, but at least one AACR NextGen Grant will be awarded to a breast cancer-focused project. Though the program, grants of up to $450,000 over three years will be awarded for any type of basic, translation, or clinical research. Letter of intent due May 5, 2020. Med-RA deadline to receive draft documents: April 22. Donaghue Foundation: Higher Value Healthcare System The Donaghue Foundation seeks to be an imaginative, collaborative, and engaged participant in the process that begins with rigorous health research and ends in realized health benefits. To advance this mission, the foundation is inviting applications for its 2020 Greater Value Portfolio grant program. The goal of the program is to test approaches and tools that organizations can readily use to improve the value of the health care they provide to their patients and communities. To that end, grants of up to $400,000 over up to two years will be awarded in support of promising approaches designed to help create a higher value healthcare system. The proposed research should be focused on developing actionable solutions to one or more of the symptoms of low value health care: high and rising healthcare costs; unwarranted variation in prices; unaffordable cost of care burden on patients and families; unacceptable variation in quality; and/or lack of transparency in both price and outcomes. Eligible approaches include models of care, coverage, or system change that seek to improve value by addressing one or more of the symptoms of low value and/or reduce routine treatments, tests, and screenings for patients for whom the potential harms (including financial harm) outweigh potential benefits; provide tools to help consumers make decisions about their healthcare based on value, including the cost of care to patients (in addition to other patient-centered factors); promote conversations between patients and their clinicians and care teams about preferences and trade-offs related to alternative treatment options and /or out of pocket cost burden to patients and families; and/or test interventions geared to reducing racial and ethnic disparities through the provision of higher value healthcare. Letter of intent due May 11, 2020. Med-RA deadline to receive draft documents: April 28. Michael J. Fox Foundation: Parkinson?s Pathway Biomarkers According to the foundation, many current Parkinson?s research efforts are focused on understanding the role of various cellular processes/pathways in PD and uncovering novel targets within these pathways for therapeutic development. As such, sensitive biomarker readouts for these pathways will be critical for bridging the gap from basic to translational research and clinical trials. The Parkinson?s Pathway Biomarkers program is open to industry and academic investigators proposing studies aimed at developing sensitive readouts for pathway activation/dysfunction and improving technologies for analyzing the target/pathway of interest. Through the program, grants of up to $300,000 will be awarded in support of studies in one or more of the following areas: biomarker studies focused on pathways that are known to be affected in PD (e.g., inflammation, mitochondrial function, lysosomal function, autophagy, protein trafficking, protein handling); studies aimed at developing novel pathway-based outcome measures or biochemical assays for PD; studies optimizing existing assays to assess PD-related pathways or pathway-based targets; and studies investigating translational biomarkers that can be assessed in preclinical models as well as patient samples. Proposals submitted for the program should focus on the development of biomarkers for pathways/targets with established relevance to PD. Pre-proposal due May 14, 2020. Med-RA deadline to receive draft documents: May 4. Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) Exploratory/Developmental Research Projects (UH2 Clinical Trial Optional) The National Institute on Alcohol Abuse and Alcoholism (NIAAA) solicits research applications to address significant challenges in Fetal Alcohol Spectrum Disorders (FASD) research in the areas of diagnosis/screening, etiology, interventions and treatment. Cooperative Agreement (UH2) applications in response to this FOA should propose exploratory/developmental projects, based on new and innovative concepts, approaches, and technologies. This solicitation is open to all eligible institutions. To maximize the impact of their research, awardees will be encouraged to establish a collaborative relationship with the NIAAA-supported Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) consortium. For this FOA no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Due May 19, 2020. Med-RA deadline to receive draft documents: May 6. Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grant (Parent T35) The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grants (T35) to eligible, domestic institutions to develop and/or enhance research training opportunities for predoctoral students interested in careers in biomedical, behavioral, or clinical research. Many NIH Institutes and Centers (ICs) use this NRSA program exclusively to support intensive, short-term research training experiences for health professional students (medical students, veterinary students, and/or students in other health-professional programs) during the summer. This program is also intended to encourage training of graduate students in the physical or quantitative sciences to pursue research careers by short-term exposure to, and involvement in, the health-related sciences. The training should be of sufficient depth to enable the trainees, upon completion of the program, to have a thorough exposure to the principles underlying the conduct of biomedical research. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 12. Addressing Racial Disparities in Maternal Mortality and Morbidity (R01 Clinical Trial Optional) This initiative will support multidisciplinary research examining mechanisms underlying racial and ethnic disparities in maternal mortality and morbidity, testing the efficacy and/or effectiveness of multi-level interventions, and/or research strategies to optimally and sustainably deliver proven-effective prevention and treatment interventions to reduce these disparities. Due May 29, 2020. Med-RA deadline to receive draft documents: May 18. NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional) The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long-term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic, or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the NIMH Strategic Plan. Due June 20, 2020; June 20, 2021; and June 20, 2022. Med-RA deadline to receive draft documents for June 20, 2020 due date: June 9. Paralyzed Veterans of America Research Fellowships and Grants: Spinal Cord Injury and Disease Overview Policies and Procedures From transplanting cells and regenerating damaged nerve fibers to designing adaptive canoe seats, the Paralyzed Veterans of America Research Foundation supports innovative research and fellowships that improve the lives of those with spinal cord injury and disease (SCI/D). The Research Foundation, a 501(c)(3) nonprofit, funds the following categories: * Basic Science - laboratory research in the basic sciences to find a cure for SCI/D. Grants funded up to $75,000 for 1 year or up to $150,000 for 2 years. * Clinical - clinical and functional studies of the medical, psychosocial and economic effects of SCI/D, and interventions to alleviate these effects. Grants funded up to $75,000 for 1 year or up to $150,000 for 2 years. * Design & Development / Assistive Technology - of assistive technology for people with SCI/D, which includes improving the identification, selection and utilization of these devices. Grants funded up to $75,000 for 1 year or up to $150,000 for 2 years. * Postdoctoral Fellowships - for postdoctoral scientists, clinicians and engineers to encourage training and specialization in the field of spinal cord research. Grants funded up to $50,000 for 1 year or up to $100,000 for 2 years. Due July 1, 2020. Med-RA deadline to receive draft documents: June 18. Utilizing Cohort Studies to Address Health Outcomes in Cancer Survivors (UG3 / UH3 Clinical Trial Not Allowed) Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support research in new and innovative cohort studies that identify clinical, lifestyle, genomic, and other factors that affect health outcomes (e.g., morbidity, mortality, quality of life, physical, social, and psychological outcomes) in cancer survivors (i.e., from diagnosis to the end of life). This FOA intends to support research that requires the creation of a new prospective cohort study that addresses a gap in knowledge pertaining to the health of cancer survivors. Applications must identify the scientific gap that the study addresses, which may include emerging treatments, less common cancer sites, and/or understudied populations of cancer survivors with disparities. Sample size and proposed data collection must be driven by the scientific questions proposed and should include information from all the following five domains in order to cover the full extent of the cancer survivor experience: 1) disease characteristics (e.g., type, stage, tumor biomarkers), 2) individual survivor characteristics (e.g., comorbidities, socioeconomic status [SES], social connections, information seeking, access to care measures), 3) treatment, treatment-related effects, and follow-up care (e.g. dose, adverse events, palliative care), 4) behavioral and lifestyle factors (e.g., diet, physical activity, adherence) and 5) quality of life outcomes (health-related quality of life (HRQOL), patient symptom reports). These domains may represent exposures and/or outcomes, depending on the research questions, and should be measured at multiple timepoints, when appropriate. The UG3/UH3 mechanism has two phases: the UG3 Planning-Exploratory Phase focused on the recruitment of study participants and data collection/utilization, and the UH3 Implementation Phase focused on completing the research agenda. Milestones to be accomplished in the UG3 phase for transition to the UH3 phase should be proposed by the Principal Investigator(s) (PIs), which will require NCI review and approval before the grant is awarded , and must include a timeline for recruitment and show feasibility for data collection and analysis. Recruitment is not required to be completed in the UG3 phase, but reasonable progress should be demonstrated to ensure that all aims will be completed in the UH3 phase. Due July 7, 2020. Med-RA deadline to receive draft documents: June 25. Mechanisms and Consequences of Sleep Disparities in the U.S. (R01 ? Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement is to promote research to understand the underlying mechanisms of sleep deficiencies among U.S. populations that experience health disparities and how sleep deficiencies may lead to disparities in health outcomes. July 14, 2020; July 14, 2021; and July 14, 2022. Med-RA deadline to receive draft documents for July 14, 2020 due date: June 29. BRAIN Initiative: Exploratory Team-Research BRAIN Circuit Programs ? eTeamBCP (U01 Clinical Trials Optional) This funding opportunity announcement (FOA) is designed to support teams of investigators that seek to cross boundaries of interdisciplinary collaboration to elucidate the contributions of dynamic circuit activity to a specific behavioral or neural system. Applications are encouraged to propose adventurous and challenging goals that can only be tackled by a synergistic team-based approach and have the potential to be transformative and/or to enable significant advances. These studies at the exploratory stage are intended for the development of experimental capabilities and/or theoretical frameworks in preparation for a future competition for larger-scale or extended efforts, including the BRAIN TargetedBCP R01 or the multi-component, Team-Research BRAIN Circuit Programs (U19). The overall goal of this FOA is to enable a large-scale analysis of neural systems and circuits within the context and during the simultaneous measurement of an ethologically relevant behavior. Toward this end, teams are expected to assemble and leverage multi-disciplinary expertise, and to integrate experimental with computational and theoretical approaches. Teams are expected to bridge fields by incorporating rich information on cell-types, on circuit functionality and connectivity, in conjunction with sophisticated analyses of an ethologically relevant behavior of an organism or a well-defined neural system. Teams are also expected to aim for a mechanistic understanding of the circuits of the central nervous system (CNS) by applying cutting-edge methods such as those for large-scale recording, manipulation, and analysis of neural circuits across multiple regions of the CNS. Due July 14, 2020 and June 15, 2021. Med-RA deadline to receive draft documents for July 14, 2020 due date: June 29. New Congressionally Directed Medical Research Program Announcements Peer Reviewed Medical Research Program Clinical Trial Award Pre-application (letter of intent): July 29, 2020. Application: August 13, 2020. Med-RA deadline to receive draft documents for application: August 3. Clinical Trial Award (for Emerging Viral Diseases and Respiratory Health) Pre-application (letter of intent): June 8, 2020. Application: June 22, 2020. Med-RA deadline to receive draft documents for application: June 9. Investigator-Initiated Research Award (for Emerging Viral Diseases and Respiratory Health) Pre-application (letter of intent): May 28, 2020. Application: June 12, 2020. Technology/Therapeutic Development Award (for Emerging Viral Diseases and Respiratory Health) Pre-application (letter of intent): May 28, 2020. Application: June 12, 2020. Med-RA deadline to receive draft documents for application: June 1. Ovarian Cancer Research Program Proteogenomics Research Award Pre-application: July 16, 2020. Application: July 30, 2020. Med-RA deadline to receive draft documents for application: July 20. Tuberous Sclerosis Complex Research Program Exploration Hypothesis Development Award Pre-application (letter of intent): June 18, 2020. Application: July 9, 2020. Idea Development Award Pre-application (letter of intent): June 18, 2020. Application: July 9, 2020. Clinical Translational Research Award Pre-application (letter of intent): June 18, 2020. Application: July 9, 2020. Med-RA deadline to receive draft documents for application: June 29. Prostate Cancer Research Program Idea Development Award Pre-application (preproposal): August 27, 2020. Application: September 24, 2020. Med-RA deadline to receive draft documents for application: September 14. Clinical Trial Award Pre-application (letter of intent): June 25, 2020. Application: July 16, 2020. Health Disparity Research Award Pre-application (letter of intent): June 25, 2020. Application: July 16, 2020. Population Science and Outcomes Research Award Pre-application (letter of intent): June 25, 2020. Application: July 16, 2020. Translational Science Award Pre-application (letter of intent): June 25, 2020. Application: July 16, 2020. Med-RA deadline to receive draft documents for application: July 6. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Wed Apr 15 10:14:00 2020 From: Research at med.fsu.edu (Med Research) Date: Wed, 15 Apr 2020 14:14:00 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE01FC5ED863@FSUCOM128.med.ad.fsu.edu> Funding for COVID-19 Projects (New Non-COVID-19-related Opportunities Follow the COVID-19 List) While FSU?s Office of Research Development is the best source for COVID-19 federal funding opportunities, below are a few that are off-the-beaten path. Terra Bradley is happy to help you pick through those at ORD or below and identify the best sources of funding for your COVID-19 projects. British Society for Antimicrobial Chemotherapy: COVID-19 Research Grants Grants of up to ?25,000 to support research projects. Exceptional grants in excess of ?25,000 will be considered. The funding scope covers projects of up to 12 months only: * New projects * Extension of existing research projects * Expenditure of staff and or consumables Applications are open worldwide to all organisations and will be subject to a rapid peer review process. Research findings will be considered for fast track open access online publication in JAC or JAC-AMR. Expressions of interest, in the form of a single-page A-4 summary should be submitted to grants at bsac.org.uk by Friday, 17 April. Given the tight deadline, please alert Med-RA as soon as possible if you intend to submit a single-page A-4 summary to this competition. Johns Hopkins Bloomberg School of Public Health: Fast-Track Grant For Research on Non-Animal Approaches to Investigate Mechanisms, Medicines, and Vaccines for Coronaviruses In response to the global COVID-19 pandemic, the Johns Hopkins Center for Alternatives to Animal Testing (CAAT) at the Bloomberg School of Public Health is redirecting part of our grant program to help accelerate the discovery of mechanisms, medicines, and vaccines for COVID-19. The program's goal is to centralize information and stimulate funding of the development of non-animal, human biology-based models to help coordinate and accelerate response to current and emerging pandemics. Funding: $40,000. Due April 30, 2020. Given the tight deadline, please alert Med-RA as soon as possible if you intend to submit to this competition. Harrington Scholar Award for Coronavirus Harrington Discovery Institute (HDI) will provide successful applicants with grant funding and expert guidance and oversight in all aspects of drug/therapeutics development, while taking no rights to intellectual property, which is retained by the award recipient and their institution. HDI will select up to ten projects through the call for proposals and its current portfolio of drugs in development. Awarded projects will run for 12 months, with the possibility of extending the engagement. Award recipients will receive: * $150k guaranteed, with the potential to receive up to $1 million in charitable support. * Dedicated drug discovery and development support from Harrington Discovery Institute?s Therapeutics Development team (experienced pharma and business development team with a track record of bringing new drugs to market). * A personalized team of drug developers and project manager for every award recipient. * Select access to partners that range from non-profit, foundation, and public sector organizations to private drug development and investment companies. Projects being sought: * Novel therapies that can target Coronavirus and its co-morbidities, such as impact on lungs and heart. * Broad-spectrum anti-viral therapies, particularly targeting respiratory viruses. * Next generation vaccines that may target new Corona strains, multiple Corona viruses or more than one type of virus. * Emergency countermeasures/prophylaxis strategies for first responders and emergency medical personnel to be administered either once or short term. Emphasis of call: * Therapies that can enter clinical trials near-term (i.e., within 12 months) with HDI project management and financial support. * Breakthrough, differentiated technologies and discoveries. Due April 30, 2020. Given the tight deadline, please alert Med-RA as soon as possible if you intend to submit to this competition. Would you like to meet with a federal agency regarding a product that you are developing for COVID-19? Request a CoronaWatch meeting. The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought. At this time, we ask for a brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note that while we will use any information you present as market research, submission is no guarantee of a meeting or funding and your submission will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure research and development. Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed. Ideal technologies and products would (but are not required to) be: * Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging Infectious Disease rapid response capabilities * Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability * Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate) Meeting requests reviewed on an ongoing basis. Please alert Med-RA as soon as possible if you intend to request a CoronaWatch meeting. SARS-CoV-2 diagnostics: performance data: A Potential Data Source and Repository for Your Data FIND is conducting independent evaluations of SARS-CoV-2 molecular tests and immunoassays. Data from these evaluations will be shared on the FIND page as soon as possible. To complement these evaluations, and in partnership with WHO in line with our official Collaborating Centre remit, we are endeavouring to centralize the collection of SARS-CoV-2 diagnostic performance data as a global public good. On 27 March 2020, we published an open call to partners and laboratories around the world for any performance data on commercially available in vitro diagnostic tests for SARS-CoV-2 that detect nucleic acid, viral antigen or antibodies. These data will be made openly accessible on our website and shared with WHO, in order to help inform procurement and implementation decisions for countries and health programmes ? specifically those with limited capacity to conduct their own independent evaluations. All data are welcome, with as much (or little) detail as possible. The data dashboard is growing daily. Use the data and / or submit your own any time. Please alert Med-RA as soon as possible if you intend to submit your data to FIND. Pfizer COVID-19 Competitive Grant Program During this challenging time, Pfizer is committed to doing all they can to respond to the COVID-19 pandemic. We recognize the need for the rapid development of educational programs and trainings and the implementation of systemic best practices for COVID19 management. As part our commitment, we are releasing this Request for Proposals (RFP) to provide financial support for organizations producing independent educational programs and quality improvement initiatives designed to combat this evolving crisis. Through this RFP, we intend to support educational programs for healthcare providers focused on the recognition, diagnosis, treatment, and overall care management of patients with COVID-19. Specific topics of interest include: * Overview of the epidemiology, virology, and clinical features of COVID19; * Summary of the criteria for testing and interpreting results of laboratory testing; * Recommendations for managing patients with COVID-19 at home and in the hospital; * Counsel for preventing transmission in the clinic and in the community; * Review of investigational treatments; * Guidance for managing special patient populations during the COVID19 pandemic; * Retraining on COVID-19 relevant medical procedures (e.g. ventilator management) for clinicians returning to the work force; * Guidelines on the correct use and procedures of personal protective equipment (PPE). In addition, we are interested in supporting programs that include tools designed to help HCP?s educate patients and caregivers on the disease state, preventative measures, and emerging strategies for COVID-19 treatment. Due May 22, 2020. Med-RA deadline to receive draft documents: May 11, 2020. Research Grant for Pandemic Preparedness The threat from newly emerging viral infections is one of the top global challenges for humanity. The recent COVID-19 pandemic shows that pandemic preparedness and having the right products and technology to fight infectious diseases with epidemic and pandemic potential is of utmost importance. It is required to act quickly to limit further substantial damages to society, economy and ecology. Project proposals will be considered that leverage modern technologies to create new breakthrough solutions to be more prepared for pandemic outbreaks or work towards existing solutions that could help to fight emerging viral infections. Proposals will be considered that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections. This is a global competition. 250,000 ?/year for 3 years with the option of extension. Pre-outbreak R&D Preparedness for pandemic disease: * Assessing the priority of pathogens and diseases with epidemic threat; * Platform technologies to accelerate the development of vaccines, drugs, diagnostics, vector control tools and delivery systems needed to control emerging health threats; * Innovative technologies for better personal protection equipment for infection control. Response during outbreak: * Novel health technologies (e.g. AI, bioelectronics, diagnostics) for early screening of potential infected patients and treatment facilitation; * Fast-track identifying, testing and production of effective drugs and vaccines during outbreak. Due August 31, 2020. Med-RA deadline to receive draft documents: August 18, 2020. Other Recently Released Non-COVID-19 Opportunities Gerber Foundation The Gerber Foundation is dedicated to enhancing the quality of life of infants and young children, with an emphasis on children under three years of age. The foundation is accepting applications for research projects aimed at identifying solutions to common everyday issues and problems in the field of children?s health and nutrition. Of particular interest to the foundation are projects offering substantial promise of meaningful advances in prevention and treatment of disease and those with broad and general applicability. Research program focus areas identified by the foundation include: Pediatric Health: Projects that promote health and prevent or treat disease. Of particular interest to the foundation are applied research projects focused on reducing the incidence of neonatal and early childhood illnesses, or those improving cognitive, social, and emotional aspects of development. Pediatric Nutrition: Projects that assure adequate nutrition to infants and young children, including applied research that evaluates the provision of specific nutrients and their related outcomes. Environmental Hazards (Nutrient Competitors): Projects that document the impact of, or ameliorate the effects of, environmental hazards on the growth and development of infants and young children. Major target areas for research include new diagnostic tools that may be more rapid, more specific, more sensitive, or less invasive; treatment regimens that are novel, less stressful or painful, more targeted, have fewer side effects, and/or provide optimal dosing; symptom relief; preventative measures; assessment of deficiencies or excesses (vitamins, minerals, drugs, etc.); and risk assessment tools or measures for environmental hazards, trauma, etc. The foundation is interested in supporting projects that will result in ?new? information, treatments, or tools that result in a change in practice; it rarely funds projects that are focused on sharing current information with parents or caregivers. Eligible applicants must be tax exempt under section 501(c)(3) of the Internal Revenue code. (Public governmental institutions such as universities are included in this definition.) With few exceptions, organizations must have their principal operations in the United States. Novice researchers follow the same process as regular grants, are limited to no more than $20,000 in total funding, and need to apply under the guidance of a mentor. Concept paper due May 15, 2020 and November 15, 2020. Med-RA deadline to receive draft documents for the May 15, 2020 deadline: May 4. Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R 21 / R01 Clinical Trials Not Allowed) R21 R01 This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. Applicants are encouraged to propose novel and innovative research that will break new ground or extend previous discoveries toward new directions. Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26. Med-RA deadline to receive draft documents for June 16, 2020 R21 standard date: June 3. Reducing Stigma Related to Drug Use in Human Service Settings (R21 / R34 Clinical Trial Optional) R21 R34 One of the most important barriers to the provision and utilization of HIV prevention and care services is stigma, which is defined as an identity marked by disgrace, disapproval or shame, which often leads to discriminatory treatment by others. This funding opportunity supports formative research to support the development of stigma reduction interventions, as well as pilot or feasibility studies of new or adapted interventions to reduce stigma that impedes the provision and utilization of HIV care and prevention services. Due August 11, 2020. Med-RA deadline to receive draft documents: July 29, 2020. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Thu Apr 16 11:04:27 2020 From: Research at med.fsu.edu (Med Research) Date: Thu, 16 Apr 2020 15:04:27 +0000 Subject: UCF NIH One-Day Virtual Conference (May 5, 2020) Message-ID: <60E19361B71BE04F835C1FB3C18361BE01FC5ED993@FSUCOM128.med.ad.fsu.edu> Forwarded on behalf of Dr. Jeffrey Joyce. Please note that the FSU/FAMU NIH workshop originally scheduled for Spring 2020 has been postponed. In the interim, the virtual conference below may be helpful. Jeffrey N. Joyce, Ph.D. Senior Associate Dean for Research and Graduate Programs Professor of Biomedical Sciences FSU CTSA PI, "Together: Transforming and Translating Discovery to improve Health" https://www.research.fsu.edu/research-fsu/ctsa/ Florida State University College of Medicine Suite 1110-J 1115 West Call Street Tallahassee, FL 32306-4300 850-644-2190 Email Jeffrey.Joyce at med.fsu.edu ORCID iD https://urldefense.com/v3/__https://orcid.org/0000-0002-0131-0946__;!!PhOWcWs!lo75kWMHViaDRrHpNH7mEhNMjSdg-gAux97WytLWUimLCGH9GDzCf0trOMb1905vRyHC8Vti9IJ-nzsmII8$ You are invited to the following event: ucf NIH One-Day virtual Conference [divider] [cid:image002.png at 01D613DC.8031F9A0] [CLICK HERE TO REGISTER BY 5/1/20] [divider] This conference aims to provide researchers across Florida Institutions with the necessary information to successfully collaborate and navigate their NIH proposals and address both practical and conceptual aspects that are important to the proposal-writing process. Presenters will include a NIH representative & UCF NIH-Funded PIs. * Tuesday, May 5, 2020 - 8:00am to 4:30pm * Agenda: https://urldefense.com/v3/__https://bit.ly/2Va3nYR__;!!PhOWcWs!lo75kWMHViaDRrHpNH7mEhNMjSdg-gAux97WytLWUimLCGH9GDzCf0trOMb1905vRyHC8Vti9IJ-cw20uhM$ * This workshop will be held virtually through Zoom. Once you register, you will receive an email with the link you will need to view the workshop. * This is a free event open to researchers across Florida institutions. * Questions? Contact: ORCWorkshops at ucf.edu [eventbrite] -------------- next part -------------- An HTML attachment was scrubbed... URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: image001.png Type: image/png Size: 212207 bytes Desc: image001.png URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: image002.png Type: image/png Size: 112467 bytes Desc: image002.png URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: image005.emz Type: application/octet-stream Size: 6181 bytes Desc: image005.emz URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: image009.png Type: image/png Size: 4590 bytes Desc: image009.png URL: From Research at med.fsu.edu Mon Apr 20 13:59:58 2020 From: Research at med.fsu.edu (Med Research) Date: Mon, 20 Apr 2020 17:59:58 +0000 Subject: FSU Funding Opportunity for COVID-19 Related Projects In-Reply-To: <678887EBDC79FB438BFD062B064C59A401A16BC621@FSUCOM128.med.ad.fsu.edu> References: <678887EBDC79FB438BFD062B064C59A401A16BC621@FSUCOM128.med.ad.fsu.edu> Message-ID: <678887EBDC79FB438BFD062B064C59A401A16BC652@FSUCOM128.med.ad.fsu.edu> Forwarded on behalf of Dr. Jeffrey Joyce. If you intend to submit a proposal to this program, please notify Med-RA at research at med.fsu.edu for assistance with approvals. Letters of intent are due April 27th, and proposals are due April 30th. ________________________________ The Office of Research Development is requesting proposals for short-term planning projects in response to the ongoing COVID-19 pandemic, and the expectation of significant amounts of federal stimulus funding later this year. This unique Collaborative Collision seed fund opportunity will provide grants up to $20,000 for short term research and planning projects related directly to the health, social, or economic impacts of the ongoing COVID-19 pandemic, and which will position teams to compete for additional, external funding within 90-120 days. Typically, Collaborative Collision seed fund grants are highly competitive, with only one to two awards per cycle. Due to the unprecedented nature of the current crisis, this round intends to fund as many high quality proposals as possible. This opportunity is also open to all FSU faculty with tenure-track or research appointments. Unlike past Collaborative Collision seed funds, participants do not need to have attended the actual event. Collaborative Collision grants are intended to allow teams to position themselves to seek external funding for a new research initiative by demonstrating a history of successful collaboration. This round of funding has unique characteristics, not found in previous Collaborative Collision Funding Opportunity Announcements. These changes are intended to facilitate rapid project development, and an accelerated competition cycle. Significant changes include a mandatory Letter of Intent and a reduction in proposal page limit. Additionally, teams may involve outside partners such as state or local government agencies, or nonprofit organizations in their efforts. Proposed projects must be directly related to understanding and/or addressing the health, social, or economic impacts of the COVID-19 pandemic. Project teams are expected to propose clear deliverables such as preliminary reports or datasets that will allow them to transition the project to external funding quickly upon the expected release of federal stimulus programs or other new funding opportunities. The Funding Opportunity Announcement document can be downloaded at : https://www.research.fsu.edu/research-offices/ord/collaborative-collision/cc-foa/ This opportunity is sponsored by the Office of the Vice President for Research. If you or your faculty have any questions please feel free to email me. Thanks, Mike Mitchell Program Manager Strategic Initiatives and Proposal Development Office of Research Development Florida State University 2019 Westcott North Annex P 850.644.9511 mike.mitchell at fsu.edu http://www.research.fsu.edu/opd/ -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Wed Apr 22 08:41:09 2020 From: Research at med.fsu.edu (Med Research) Date: Wed, 22 Apr 2020 12:41:09 +0000 Subject: Precision Health Funding Opportunity funded by the UF-FSU CTSA hub In-Reply-To: <1040FAB8-E759-46D6-96FD-631B62CCB00A@med.fsu.edu> References: <1040FAB8-E759-46D6-96FD-631B62CCB00A@med.fsu.edu> Message-ID: <678887EBDC79FB438BFD062B064C59A401A16BCC1F@FSUCOM128.med.ad.fsu.edu> Forwarded on behalf of Dr. Jeffrey Joyce. If you intend to respond to this opportunity, please notify Terra Bradley at Terra.Bradley at med.fsu.edu. The funding opportunity and application documents are attached and linked below. Applications are due May 15, 2020. [https://urldefense.com/v3/__https://gallery.mailchimp.com/125be93dc214597c36db124d4/images/c222166f-16a7-40a0-9be3-8d163ee2e731.png__;!!PhOWcWs!mJ6MJSGhIj0KTfOVpUJkChIHxuu8CYAzHI-QF5MFkrHO3L-5a5kwDglHKXZv6H1N6LMwQjS_D3Im3yJfK3A$ ] [https://urldefense.com/v3/__https://gallery.mailchimp.com/125be93dc214597c36db124d4/images/824e0859-0b1d-4bbe-95f9-286ad6558b96.jpg__;!!PhOWcWs!mJ6MJSGhIj0KTfOVpUJkChIHxuu8CYAzHI-QF5MFkrHO3L-5a5kwDglHKXZv6H1N6LMwQjS_D3ImZyMPtu8$ ] CTSI Precision Health Initiative Pilot Funding Opportunity Applications accepted through May 15, 2020 Attend an information session on April 28 (details below) As part of the Clinical and Translational Science Award collaboration between the University of Florida and Florida State University, we welcome proposals in response to this RFA that support the development of methods, interventions or integrative models with the potential to advance precision health. Precision Health Pilot Projects may involve any combination of multisource data, including but not limited to molecular (e.g., genomics, metabolomics, proteomics); imaging (e.g., MRI, pathology slides, or dermatology images); patient-generated (e.g., mobile health devices or apps); clinical (e.g., electronic health records or devices, insurance claims); public health surveillance; social determinants of health; economic; or environmental. See below for details on an upcoming information session and resources that might be helpful to applicants. To view the full RFA and application, visit our website here or download the RFA here. Definitions Precision Medicine An ?approach for disease prevention and treatment that takes into account individual differences in lifestyle, environment, and biology.? - NIH All of Us Program: https://urldefense.com/v3/__https://allofus.nih.gov/about/about-all-us-research-program__;!!PhOWcWs!mJ6MJSGhIj0KTfOVpUJkChIHxuu8CYAzHI-QF5MFkrHO3L-5a5kwDglHKXZv6H1N6LMwQjS_D3ImFWb1pP0$ Precision Public Health "Improving the ability to prevent disease, promote health, and reduce health disparities in populations by: 1) applying emerging methods and technologies for measuring disease, pathogens, exposures, behaviors, and susceptibility in populations; 2) developing policies and targeted implementation programs to improve health.? - Precision Public Health and Precision Medicine: Two Peas in a Pod (https://urldefense.com/v3/__https://blogs.cdc.gov/genomics/2015/03/02/precision-public__;!!PhOWcWs!mJ6MJSGhIj0KTfOVpUJkChIHxuu8CYAzHI-QF5MFkrHO3L-5a5kwDglHKXZv6H1N6LMwQjS_D3Im5rTTXS0$ /) Funding and awards Pilot project grants are one-year competitive awards, up to $50,000, to provide funding for early stage projects. Funding priority for this year?s program will be given to meritorious proposals utilizing OneFlorida data. Eligibility * This call is open to investigators at UF and Florida State University (FSU). Applicants are strongly encouraged to include an investigator from each institution, and principal investigators (PIs) must meet the requirements for PI status as specified by their home institution. * Applicants must assemble project teams that include investigators from at least two colleges, and must include at least one trainee (i.e., graduate student, postdoc, resident) or junior faculty member for a mentored research experience. Single-investigator proposals are not eligible. * Applicants can only submit one application for which they are the PI, but individuals can be listed as co-investigators on more than one proposal. * Recipients of previous CTSI Pilot Awards are eligible to apply for awards to support fundamentally new research projects, as long as previous projects have been completed. * Animal studies are not allowed. Deadlines Applications can be submitted in response to this RFA on any date between April 17, 2020 and May 15, 2020 (by 5 p.m.) to elizabetheddy at ufl.edu (UF) or terra.bradley at med.fsu.edu (FSU). Successful applicants will have up to 12 months from date of NIH approval to complete their projects. Information Sessions Questions? Please join us via Zoom on Tuesday, April 28, 2020 from 10:00 AM to 11:00 AM to hear from CTSI Precision Health Initiative leaders. Contact Please email questions to elizabetheddy at ufl.edu (UF) or terra.bradley at med.fsu.edu (FSU). Applicants are encouraged to visit the CTSI website to learn about additional services available to facilitate research at UF. Additional resources for applicants The following resources may be of interest for potential projects: UF CTSI services and resources: * Pilot Grantwriters? Toolkit * UF Health Precision Medicine Program * UF HSC Libraries Guide: Precision Public Health * Biostatistics, Epidemiology and Research Design Program * Biomedical Informatics Program * Southeast Center for Integrated Metabolomics open-source tools * UF Health Integrated Data Repository * OneFlorida Data Trust * For additional CTSI research services, visit: https://urldefense.com/v3/__https://www.ctsi.ufl.edu/research/__;!!PhOWcWs!mJ6MJSGhIj0KTfOVpUJkChIHxuu8CYAzHI-QF5MFkrHO3L-5a5kwDglHKXZv6H1N6LMwQjS_D3Im8G8DCuk$ * For remote recruitment resources during COVID-19, visit: https://urldefense.com/v3/__https://www.ctsi.ufl.edu/covid-19-research-project-assistance/__;!!PhOWcWs!mJ6MJSGhIj0KTfOVpUJkChIHxuu8CYAzHI-QF5MFkrHO3L-5a5kwDglHKXZv6H1N6LMwQjS_D3ImwSDltbg$ * UF Informatics Institute fellows programs, student organization and other resources * UFIT Research Computing resources: HiPerGator, ResShield and ResVault -------------- next part -------------- An HTML attachment was scrubbed... URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: CTSIPrecisionHealth_Spring2020PilotRFA_Final.pdf Type: application/pdf Size: 704586 bytes Desc: CTSIPrecisionHealth_Spring2020PilotRFA_Final.pdf URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: CTSI_PH_Pilot_Application2020_Final.pdf Type: application/pdf Size: 429065 bytes Desc: CTSI_PH_Pilot_Application2020_Final.pdf URL: From Research at med.fsu.edu Fri Apr 24 14:46:02 2020 From: Research at med.fsu.edu (Med Research) Date: Fri, 24 Apr 2020 18:46:02 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A16BE348@FSUCOM128.med.ad.fsu.edu> PCORI Funding Announcement COVID-19: Opens May 5 In order to respond to the COVID-19 pandemic, PCORI intends to publish a new research funding announcement to support innovative, high-impact studies that fit clearly within our core mission of patient-engaged and patient-centered comparative clinical effectiveness research. The objectives of this announcement are to (1) strengthen the understanding of different approaches to mitigate the impact of COVID-19 on individuals, communities, healthcare providers, and healthcare systems; and (2) provide evidence to inform clinical and public health responses, decision making, and planning. PCORI will encourage the use of diverse methods, including interventional studies and the use of natural experiments, to conduct research on an accelerated timeline with the ability to complete primary outcomes collection and provide actionable findings in no longer than 12 months. Hybrid designs, which can provide insight into implementation approaches in the context of evidence generation, will also be welcome. Applicants should be prepared to work independently and/or with PCORI to expedite dissemination of results. Please note that this funding announcement follows an expedited timeline. Applications are due three weeks following the posting of the PFA. We encourage applicants to begin working on all components of the proposal, including a detailed budget, as soon as possible. This funding announcement has three targeted priority areas. The research questions articulated in each of the priority areas below are not the only questions of interest; other relevant questions within these priority areas will also be considered. The priority areas are: * Adaptations to healthcare delivery: What has been the impact on patient-centered outcomes of alternative healthcare delivery models (e.g., telehealth, hospital at home) that are being implemented in response to COVID-19? What has been learned about barriers and facilitators to their effective implementation? * Impact of COVID-19 on vulnerable populations: What are effective clinical pathways to improve outcomes for the most vulnerable and higher risk patients? What are effective system- or organizational-level responses to prevent or mitigate impact of COVID-19 in low-income and low-resource settings that serve vulnerable populations? Vulnerable populations include but are not limited to Native Americans or Alaskan Natives, African Americans, and other racial, ethnic, or sexual and gender minorities; rural communities; incarcerated populations; people who are homeless or unstably housed; individuals with intellectual, developmental, or physical disabilities; individuals with chronic conditions; and individuals facing increased exposure because they are unable to work remotely. * Impact of COVID-19 on healthcare workforce well-being, management, and training: What policies, practices, or programs are effective in helping health systems quickly shift human resources, redeploy healthcare workers, and train current and new healthcare workers to fill certain healthcare delivery needs? What are effective strategies to protect the physical and/or mental well-being of the health care workforce? Due May 26, 2020. Med-RA deadline to receive draft documents: May 12. Pfizer: Acromegaly/Growth Hormone Excess Research Under the RFP, grants of up to $100,000 will be awarded in support of research projects with the potential to advance medical knowledge of acromegaly disease, including its complications and treatment with pegvisomant. Projects submitted may include morbidity and mortality in patients with Acromegaly/GH Excess; laboratory investigations on effects of pegvisomant; clinical outcomes, quality of life, and patient-reported outcomes associated with monotherapy or combination therapy, including pegvisomant; and pharmacoeconomics such as but not limited to resource utilization, patient-reported outcomes, and treatment patterns. Due May 28, 2020. Med-RA deadline to receive draft documents: May 14. Caplan Foundation for Early Childhood Grants The Caplan Foundation for Early Childhood is an incubator of promising research and development projects that appear likely to improve the welfare of young children, from infancy through 7 years, in the United States. Welfare is broadly defined to include physical and mental health, safety, nutrition, education, play, familial support, acculturation, societal integration and childcare. Grants are only made if a successful project outcome will likely be of significant interest to other professionals, within the grantee?s field of endeavor, and would have a direct benefit and potential national application. The Foundation?s goal is to provide seed money to implement those imaginative proposals that exhibit the greatest chance of improving the lives of young children, on a national scale. Because of the Foundation?s limited funding capability, it seeks to maximize a grant?s potential impact. * Early Childhood Welfare: Children can only reach their full potential when all aspects of their development ? intellectual, emotional and physical ? are supported. Providing a safe and nurturing environment for infants and preschoolers is essential, as is imparting to them the skills of living in a culturally diverse world. To that end, the foundation supports programs that research best child-rearing practices and identify models that can provide creative, caring environments in which all can children thrive. * Early Childhood Education and Play: Research shows that children need to be stimulated as well as nurtured early in life if they are to succeed in school, work, and life. That preparation relates to every aspect of a child?s development, and everywhere a child learns ? at home, in childcare settings and in preschool. The foundation seeks to improve the quality of both early childhood teaching and learning through the development of innovative curricula and research based pedagogical standards, as well as the design of imaginative play materials and learning environments. * Parenting Education: To help parents create nurturing environments for their children, the foundation supports programs that teach parents about developmental psychology, cultural child-rearing differences, pedagogy, issues of health, prenatal care, and diet, as well programs that provide both cognitive and emotional support to parents. Letter of inquiry due May 31, 2020. Med-RA deadline to receive draft documents: May 18. Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations. Standard dates apply. Expires September 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26. Pfizer: Providing Advanced Medical Support for Patients with Primary Immunodeficiency (PI) Disorders Through this RFP it is our intent to support patient-focused programs that help patients and providers address the heightened medical and educational needs of patients with PI during this pandemic. Priority will be awarded to projects that leverage the utilization of innovative technology platforms for distant learning to reach the intended audience with a focus on patient outreach, medical support and telework. Target audience for programs: Primary care practitioners, specialists, infusion nurses, pharmacists, nurse practitioners, physician assistants, patient advocacy groups and the patients with PI they manage and treat. Individual projects requesting up to $250,000 will be considered. Due June 8, 2020. Med-RA deadline to receive draft documents: May 26. Melanoma Research Program Idea Award Pre-application: June 22, 2020. Application: September 24, 2020. Mid-Career Accelerator Award Pre-application: June 22, 2020. Application: September 24, 2020. Team Science Award Pre-application: June 22, 2020. Application: September 24, 2020. Technology Development Partnership Award Pre-application: June 22, 2020. Application: September 24, 2020. Translational Research Award Pre-application: June 22, 2020. Application: September 24, 2020. Translational Research Award ? Collaborator Option Pre-application: June 22, 2020. Application: September 24, 2020. Med-RA deadline to receive draft documents for pre-application: June 9. Robert Wood Johnson Foundation: Pioneering Ideas--Culture of Health As our current reality underscores, we live in a dynamic world?where unforeseen global events; new technologies; scientific discoveries; changes in our climate, economy, demographics; and more?continually shape where and how we live, learn, work and play. These changes will profoundly impact health equity in our society, from our individual health and the health of our families to the health of our communities. What dramatic changes might we see in the next 5 to 15 years? What can we do today to create a better, more equitable tomorrow? We seek to answer these questions, anticipate the future, and support unconventional approaches and breakthrough ideas that can help lead the way to a future where everyone in the United States can live their healthiest life possible. Pioneering Ideas: Exploring the Future to Build a Culture of Health seeks proposals that are primed to influence health equity in the future. We are interested in ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, we welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health. We want to hear from scientists, anthropologists, artists, urban planners, community leaders?anyone, anywhere who has a new or unconventional idea that could alter the trajectory of health, and improve health equity and well-being for generations to come. The changes we seek require diverse perspectives and cannot be accomplished by any one person, organization or sector. Proposals will be accepted throughout the year (2020) on a rolling basis. Med-RA deadline to receive draft documents is 10 business days before application submission. FSU: Robert B. Bradley Library Research Grants This announcement is an invitation to faculty to apply for the annual Robert B. Bradley Library Research Grants, which support the research and creative endeavors of our faculty while developing our library?s world class collections. Bob Bradley (retired VP for Planning and Programs at FSU) has been a longtime supporter of the University Libraries, and he has advocated consistently for resources to support the centrality of the libraries that play such an important role in the scholarly work of our faculty. In 2020-2021 the Faculty Senate Library Committee will have a total of $100,000 to support the research and creative work of faculty with new library acquisitions accessible for the whole FSU community. Please consider preparing your brief mini-grant application over the summer, as all application materials are due in October. Due October 9, 2020. Pfizer: Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Projects that will be considered for Pfizer support will focus on improving the care of patients by: * Closing knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and treatment paradigms * Addressing barriers to diagnosis and strategies that reduce burdens for patients and providers along the pathway to diagnosis * Exploring strategies that empower patients to play an active role in understanding ATTR-CM and available diagnostic and treatment options * Increasing awareness of the changing epidemiology of ATTR-CM with a focus on the prevalence of hereditary-and wild-type subtypes in the modern era * Highlighting disease disparities for different hereditary ATTR mutations that have cardiomyopathy or mixed cardiomyopathy/neuropathy phenotypes * Increasing awareness of at risk and undiagnosed populations with ATTR-CM with a focus on improving strategies that facilitate the diagnosis of patients early in the disease course before advanced cardiomyopathy has ensued * Increasing awareness of non-invasive diagnostic modalities to raise suspicion for ATTR-CM * Increasing awareness of bone radiotracer scintigraphy as a non-invasive alternative to invasive endomyocardial biopsy for the diagnosis of ATTR-CM in select patients * Supporting the dissemination of information related to the study of treatment options and monitoring response to therapy to improve patient important outcomes in ATTR-CM Target audience for programs: General Cardiologists, Heart Failure Nurses, Heart Failure Specialists, Echocardiographers, Nuclear Cardiologists, Primary Care Physicians in the Local Setting. Individual projects requesting up to $10,000 will be considered for small local/community programs. Individual projects requesting up to $20,000 will be considered for large local/community programs. Note: This RFP will remain open while funds last. Once the full budget is spent the RFP will be closed and new requests will no longer be accepted. Due October 30, 2020. Med-RA deadline to receive draft documents: October 19. New Informatics Tools and Methods to Enhance U.S. Cancer Surveillance Research (U01 Clinical Trial Optional) The goal of this Funding Opportunity Announcement (FOA) is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely, and accurate data collection by cancer registries. Specifically, the FOA solicits applications for projects to develop, adapt, apply, scale-up, and validate tools and methods to improve the collection and integration of cancer registry data to expand the data items collected. Applications proposed must be based on partnership with at a minimum of two U.S. population-based central cancer registries. Tools and methods proposed for development are expected to enhance the registry core infrastructure and, in so doing, expand the usefulness of registry-collected data to support high-quality cancer research. The scientific scope of this FOA includes but is not limited to * Development, validation, evaluation of scalable tools/methods to facilitate automatic/unsupervised extraction and cosolidation of specific data from various types of unstructured medical records as for example, pathology reports, diagnostic imaging, laboratory, hospital discharge forms and clinical visits; * Supplementation of cancer registries with new or more detailed data items, from existing data sources or from linkages with novel data sources, e.g. electronic medical records (EMR). Due November 18, 2020; June 6, 2021; November 18, 2021; June 6, 2022; and November 18, 2022; June 6, 2023. Med-RA deadline to receive draft documents for November 18, 2020 deadline: November 4. Implementation Research to Improve Case Finding, Cascade Screening, and Treatment for Familial Hypercholesterolemia (FH) (R61 / R33 Clinical Trial Required) This milestone-driven Funding Opportunity Announcement (FOA) invites applications for single site clinical trials to: (1) address barriers that impede population-level implementation of case finding and cascade screening (i.e., blood relatives of familial hypercholesterolemia (FH) index cases are systematically contacted based on their risk according to the pattern of inheritance); (2) explore implementation science methodologies to assess the uptake, cost-effectiveness, feasibility, and scalability of family-based cascade screening programs for FH; (3) develop or improve machine learning algorithms and data mining techniques to find high-risk individuals using Electronic Health Records (EHRs); and (4) optimize treatment strategies and health outcomes. Due March 8, 2021. Med-RA deadline to receive draft documents: February 23. Macy Foundation: Medical Education Grants At the Josiah Macy Jr. Foundation, we aim to prepare future health professionals to meet the needs of the 21st century with a population that is the most diverse in U.S. history and who may live longer than any previous generation. We are focusing on the learning environments where our future health professionals train so that they learn not only prevention and the social determinants of health but are well prepared to care for people when they are ill. This means learning the scientific basis of disease and taking advantage of the discoveries and breakthroughs in diagnosis and treatment so that they make wise choices while providing compassionate care. We foster innovation in clinical learning environments by investing in three areas: * Promoting Diversity, Equity, and Belonging * Increasing Collaboration Among Future Health Professionals * Preparing Future Health Professionals to Navigate Ethical Dilemmas Board Grants: Board Grants are generally one to three years in duration. Board Grants are selected three times each year at our board meetings. Required letter of inquiry: Submit anytime. President?s Grants: President?s Grants can be given at any time and are evaluated and awarded by our president. President?s Grants usually align with our priority areas. In general, President?s Grants are one year or less in duration and awarded amounts are no more than $35,000. Application: Submit anytime. Med-RA deadline to receive draft documents is 10 business days before application submission. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: